| ECL |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.11 vs. cons $2.08 |
MEDIUM |
| ECL |
Report |
Organic sales growth |
IN-LINE |
pred ~4.5% vs. cons 4.6% |
MEDIUM |
| ECL |
Report |
Adjusted operating-income margin |
BEAT |
pred ~17.2% vs. cons 17.0% |
MEDIUM |
| ECL |
Guide |
Full-year 2026 adjusted diluted EPS outlook, excluding CoolIT |
UNCHANGED |
guide ~$8.53 midpoint vs. cons $8.54 (FY2026) |
HIGH |
| ECL |
Guide |
Second-half organic sales-growth outlook |
BETTER |
guide ~6.5% vs. cons 6.3% (2H2026) |
MEDIUM |
| ECL |
Guide |
Third-quarter adjusted diluted EPS outlook, excluding CoolIT |
LOWER |
guide ~$2.29 midpoint vs. cons $2.33 (3Q2026) |
MEDIUM |
| ECL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| ECL |
Return |
5-day cumulative residual |
+1.2% (STABILIZE) |
A ~$2.11 vs. $2.08 EPS beat and ~17.2% vs. 17.0% margin support an initial positive move, but unchanged ~$8.53 vs. $8.54 FY2026 EPS and a ~$2.29 vs. $2.33 3Q outlook limit out-period estimate revisions. |
MEDIUM |